These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12820463)

  • 1. Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies.
    de Vries MR; ten Hagen TL; Marinelli AW; Eggermont AM
    Anticancer Res; 2003; 23(2C):1811-23. PubMed ID: 12820463
    [No Abstract]   [Full Text] [Related]  

  • 2. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
    Nakamoto T; Inagawa H; Takagi K; Soma G
    Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tumor necrosis factor in isolated hepatic perfusion.
    Fraker DL; Alexander HR; Thom AK
    Circ Shock; 1994 Sep; 44(1):45-50. PubMed ID: 7704938
    [No Abstract]   [Full Text] [Related]  

  • 4. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
    Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ
    Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated hepatic perfusion for the treatment of liver tumors: sunset or sunrise?
    Verhoef C; de Wilt JH; ten Hagen TL; Eggermont AM
    Surg Oncol Clin N Am; 2008 Oct; 17(4):877-94, xi. PubMed ID: 18722924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional immunotherapy for liver metastases and the potential of TNF alpha in hepatic perfusion from laboratory to the clinic.
    Eggermont AM
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1371-8. PubMed ID: 8854756
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies.
    Jones A; Alexander HR
    Surg Oncol Clin N Am; 2008 Oct; 17(4):857-76, x. PubMed ID: 18722923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors.
    Lowy AM; Curley SA
    Surg Oncol Clin N Am; 1996 Apr; 5(2):429-41. PubMed ID: 9019362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors.
    Rothbarth J; Tollenaar RA; van de Velde CJ
    Expert Rev Anticancer Ther; 2006 Apr; 6(4):553-65. PubMed ID: 16613543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases.
    Dizon DS; Schwartz J; Kemeny N
    Surg Oncol Clin N Am; 2008 Oct; 17(4):759-71, viii. PubMed ID: 18722916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The past decade of experience with isolated hepatic perfusion.
    Grover A; Alexander HR
    Oncologist; 2004; 9(6):653-64. PubMed ID: 15561809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver.
    Alexander HR; Bartlett DL; Libutti SK
    Cancer J Sci Am; 1998; 4(1):2-11. PubMed ID: 9467038
    [No Abstract]   [Full Text] [Related]  

  • 13. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors.
    Ku Y; Tominaga M; Iwasaki T; Fukumoto T; Kuroda Y
    Int J Clin Oncol; 2002 Apr; 7(2):82-90. PubMed ID: 12018114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where are we going with regional therapy for melanoma?
    Tyler D
    Ann Surg Oncol; 2004 May; 11(5):455-7. PubMed ID: 15078631
    [No Abstract]   [Full Text] [Related]  

  • 15. Bio-chemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques.
    van Ijken MG; van Etten B; Brunstein F; ten Hagen TL; Guetens G; de Wilt JH; de Bruijn EA; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):807-16. PubMed ID: 15951150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives.
    Eggermont AM
    Anticancer Res; 1998; 18(5D):3899-905. PubMed ID: 9854502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.
    Lejeune FJ
    J Clin Invest; 2002 Aug; 110(4):433-5. PubMed ID: 12189235
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolated hepatic perfusion: experimental evidence and clinical utility.
    de Wilt JH; van Etten B; Verhoef C; Eggermont AM
    Surg Clin North Am; 2004 Apr; 84(2):627-41. PubMed ID: 15062665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of hyperthermic limb perfusion for in-transit melanoma.
    Ross MI
    Int J Hyperthermia; 2008 May; 24(3):205-17. PubMed ID: 18392999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretic and experimental aspects of regional liver infusion.
    August DA
    Surg Oncol Clin N Am; 1996 Apr; 5(2):399-409. PubMed ID: 9019360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.